1. Residual macrovascular risk in 2013: what have we learned?;Fruchart;Cardiovasc. Diabetol.,2014
2. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein;Ridker;N. Engl. J. Med.,2008
3. Intensive versus moderate lipid lowering with statins after acute coronary syndromes;Auer;N. Engl. J. Med.,2004
4. Intensive lipid lowering with atorvastatin in coronary disease;Auer;N. Engl. J. Med.,2005
5. Bhatt DL, Santos V, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet 394, 1169 – 1180.